• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Proteasome Inhibitor
    4 Drugs classified under this drug class


    All the Drug Class Drugs

    Bortez Teva
    Abic
    RX
    partial basket chart
    Bortez Teva

    Proteasome Inhibitor. Bortezomib 3.5 mg.
    VIAL (Pwdr. for sol. for IV/SC inj.): 1. Init. dose of Bortezomib is 1.3mg/m², may be admin. IV at a conc. of 1 mg/mL, or SC at a conc. of 2.5 mg/mL. When admin. IV, the drug  is admin. as a 3-5 sec.  bolus IV inj.
    Because each route of admin. has a different reconstituted conc., caution should be used when calculat. the volume to be admin. This med. is for IV or SC use only, must not be admin. by any other route. Intrathecal admin. has resulted in death. Dose must be individualized. See lit.
    Tmt. of pts. with multiple myeloma.
    Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther.
    Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone is indic. for the tmt. of adult pts. with prev. untreat. mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplant.
    C/I: Hypersens. (not include. local react.) to bortezomib, boron, or mannitol. React. have include. anaphyl. react.
    Pts. with acute diffuse infiltrative pulmon. & pericard. dis. Intrathecal admin.

    Bortezomib Teva 3.5 mg
    Abic
    RX
    partial basket chart
    Bortezomib Teva 3.5 mg

    Proteasome Inhibitor. Bortezomib 3.5 mg.
    VIAL (pwdr. for sol. for inj. SC IV):1×3.5mg.
    Initial.  is 1.3 mg/m2. may be admin. IV  at a concent.  of 1 mg/mL, or SC at a concent. of 2.5 mg/mL. When admin. IV, Bortezomib is admin. as a 3 -5 second bolus IV inj. Not for intrathecal use. See lit.
    Tmt. of pts.  with multip.myeloma. Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther. Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone- tmt. of adult pts. with prev. untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplant.
    C/I: Pts. with hypersens. (not includ. local react.), anaphylactic react.  to bortezomib, boron, or mannitol. Pts. with acute diffuse  infiltrative pulmon. and pericard. dis. Intrathecal   admin. (due to fatal events).

    Kyprolis
    Amgen
    RX
    partial basket chart
    Kyprolis

    Proteasome Inhibitor. Carfilzomib 60 mg/vial.
    SINGLE USE VIALS (Pwdr. for sol. for
    inject.): I.V. over 2 to 10 min., on Days 1,
    2, 8, 9, 15, 16, foll. by a rest period from
    Days 17 to 28. Ea. 28day period is 1 tmt
    cycle. In Cycle 1, a dose is 20 mg/m².
    Dose must be indiv. adjust. accord.
    with med. cond. and param. Modify
    dos. based on toxic.
    Tmt. of pts. with multiple myeloma who
    have receiv. at least 2 prior ther. incl.
    bortezomib and an immunomodul. ag.
    and have demonstr. dis. progress. on or
    within 60 days of compl. the last ther.
    Appr. is based on response rate. Clinical
    benefit, such as impr. in surv./sympt., has
    not been verified.
    C/I: None.

    Velcade
    Janssen
    RX
    partial basket chart
    Velcade

    Proteasome Inhibitor. Bortezomib 3.5 mg.
    VIAL (pwdr for sol.): 1. Initial: 1-3 mg/m2 2
    x wkly for 2 wks (days 1, 4, 8, and 11)
    foll. by 10 day rest period (days 12-21).
    This 3 wk. period is a tmt. cycle. At
    least 72 hrs. should elapse betw.
    consec. doses. See lit.
    Myeloma in pts. who have receiv. at least
    two prior therapies and have shown
    disease progress. on the last ther.
    C/I: Hypersens., severe hepat. impair.

    CLOSE